Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Health Professional Version.

PDQ Integrative, Alternative, and Complementary Therapies Editorial Board.

PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.
2019 Jun 5.

2.

Genetics of Prostate Cancer (PDQ®): Health Professional Version.

PDQ Cancer Genetics Editorial Board.

PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.
2019 Jun 7.

3.

Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.

Jang YG, Go RE, Hwang KA, Choi KC.

J Steroid Biochem Mol Biol. 2019 Jun 8;192:105406. doi: 10.1016/j.jsbmb.2019.105406. [Epub ahead of print]

PMID:
31185279
4.

Quantitative contrast-enhanced perfusion kinetics in multiparametric MRI in differentiating prostate cancer from chronic prostatitis: results from a pilot study.

Sureka B, Elhence P, Khera PS, Choudhary GR, Pandey H, Garg PK, Yadav K, Goel A.

Br J Radiol. 2019 Jun 11:20190181. doi: 10.1259/bjr.20190181. [Epub ahead of print]

PMID:
31184934
5.

Cancer treatment and survivorship statistics, 2019.

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL.

CA Cancer J Clin. 2019 Jun 11. doi: 10.3322/caac.21565. [Epub ahead of print]

6.

Re: Metabolomic prostate cancer fields in HRMAS MRS-profiled histologically benign tissue vary with cancer status and distance from cancer. Dinges et al, NBM 2019.

Bourne R.

NMR Biomed. 2019 Jun 11:e4121. doi: 10.1002/nbm.4121. [Epub ahead of print] No abstract available.

PMID:
31184774
7.

Dihydrotestosterone increases cytotoxic activity of macrophages on prostate cancer cells via TRAIL.

Lee GT, Kim JH, Kwon SJ, Stein MN, Hong JH, Nagaya N, Billakanti S, Kim MM, Kim WJ, Kim IY.

Endocrinology. 2019 Jun 11. pii: en.2019-00367. doi: 10.1210/en.2019-00367. [Epub ahead of print]

PMID:
31184711
8.

Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging.

Muñoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, Freund AM, Rodier F, Wu JD, Desprez PY, Raulet DH, Nelson PS, van 't Veer LJ, Campisi J, Coppé JP.

JCI Insight. 2019 Jun 11;5. pii: 124716. doi: 10.1172/jci.insight.124716.

9.

PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway.

Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, Thoeny HC, Macura KJ, Tempany CM, Verma S, Weinreb JC, Cornud F, Haider MA.

Radiology. 2019 Jun 11:182946. doi: 10.1148/radiol.2019182946. [Epub ahead of print]

PMID:
31184561
10.

Dietary Glycemic Index and Glycemic Load and the Risk of Prostate Cancer: An Updated Systematic Review and Dose-Response Meta-Analysis.

Sadeghi A, Sadeghi O, Khodadost M, Pirouzi A, Hosseini B, Saedisomeolia A.

Nutr Cancer. 2019 Jun 11:1-10. doi: 10.1080/01635581.2019.1621356. [Epub ahead of print]

PMID:
31184513
11.

Re: The role of 68Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer.

Cihan YB.

Int Braz J Urol. 2019 May 15;45. doi: 10.1590/S1677-5538.IBJU.2019.0130. [Epub ahead of print] No abstract available.

PMID:
31184450
12.

Rosa canina Extract has Antiproliferative and Proapoptotic Effects on Human Lung and Prostate Cancer Cells.

Kilinc K, Demir S, Turan I, Mentese A, Orem A, Sonmez M, Aliyazicioglu Y.

Nutr Cancer. 2019 Jun 11:1-10. doi: 10.1080/01635581.2019.1625936. [Epub ahead of print]

PMID:
31184219
13.
14.

Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.

Ito K, Oki R, Sekine Y, Arai S, Miyazawa Y, Shibata Y, Suzuki K, Kurosawa I.

Int J Urol. 2019 Jun 10. doi: 10.1111/iju.14039. [Epub ahead of print] Review.

PMID:
31183923
15.

Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.

Hongo F, Okihara K, Kitamura K, Fujihara A, Yamada Y, Shiraishi T, Konishi E, Ukimura O.

Int J Urol. 2019 Jun 10. doi: 10.1111/iju.14037. [Epub ahead of print]

PMID:
31183899
16.

Enhancing Prostate-Cancer-Specific MRI by Genetic Amplified Nanoparticle Tumor Homing.

Zhao Y, Peng J, Yang J, Zhang E, Huang L, Yang H, Kakadiaris E, Li J, Yan B, Shang Z, Jiang N, Zhang X, Han G, Niu Y.

Adv Mater. 2019 Jun 11:e1900928. doi: 10.1002/adma.201900928. [Epub ahead of print]

PMID:
31183895
17.

Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy.

Wu S, Lin SX, Lu M, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL.

Int Urol Nephrol. 2019 Jun 10. doi: 10.1007/s11255-019-02181-7. [Epub ahead of print]

PMID:
31183659
18.

Anticancer evaluation of a novel dithiocarbamate hybrid as the tubulin polymerization inhibitor.

Liu J, Xue D, Zhu X, Yu L, Mao M, Liu Y.

Invest New Drugs. 2019 Jun 10. doi: 10.1007/s10637-019-00799-z. [Epub ahead of print]

PMID:
31183632
19.

Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry.

Johansen TEB, Zahl PH, Baco E, Bartoletti R, Bonkat G, Bruyere F, Cai T, Cek M, Kulchavenya E, Köves B, Mouraviev V, Pilatz A, Tandogdu Z, Tenke P, Wagenlehner FME.

World J Urol. 2019 Jun 10. doi: 10.1007/s00345-019-02837-0. [Epub ahead of print] Review.

PMID:
31183524
20.

Tumor-Activatable Clinical Nanoprobe for Cancer Imaging.

Reichel D, Tripathi M, Butte P, Saouaf R, Perez JM.

Nanotheranostics. 2019 May 4;3(2):196-211. doi: 10.7150/ntno.34921. eCollection 2019.

Supplemental Content

Loading ...
Support Center